Rationale for treatment of hepatitis C virus infection in end-stage renal disease patients who are not kidney transplant candidates
| Autor: | Craig E. Gordon, Terry Box, Adhish Agarwal, Isaac Hall, Huy Thien-Tuan Tran, Catreena Al-Marji, Laith Al-Rabadi, Girish Singhania |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Elbasvir
medicine.medical_specialty business.industry Hepatitis C virus medicine.medical_treatment 030232 urology & nephrology Hematology Glecaprevir medicine.disease_cause medicine.disease Pibrentasvir End stage renal disease 03 medical and health sciences 0302 clinical medicine Grazoprevir Nephrology Internal medicine medicine 030211 gastroenterology & hepatology Hemodialysis business Kidney transplantation |
| Zdroj: | Hemodialysis International. 22:S45-S52 |
| ISSN: | 1492-7535 |
| Popis: | Hepatitis C virus (HCV) infection is a common problem in patients treated with maintenance hemodialysis (HD) and is associated with an increased morbidity and mortality and lower quality of life. The major causes of HCV-associated mortality are liver and cardiovascular-related death. HCV-infected HD patients have a higher prevalence of inflammation-related metabolic and vascular diseases, leading to high rates of cardiovascular mortality in patients with end-stage renal disease. In the current era of highly effective direct-acting antiviral regimens, HCV treatment may also confer hepatic, cardiovascular and other morbidity and mortality benefits even to dialysis-dependent patients who do not qualify for kidney transplantation. Currently, the most accepted regimens in this patient population include elbasvir/grazoprevir and glecaprevir/pibrentasvir. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text